Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6X4IT)

Drug Name

MDL-28133A Drug Info

Synonyms

Mdl 28133A; 136861-96-6; N-[4-[1-[2-(4-fluorophenyl)-2-oxo-ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide hydrochloride; Mdl-28,133A; ACMC-20mwcf; AC1L307E; CTK0H5594; DTXSID60159987; 1-(4-Fluorophenyl)-2-(4-((4-methanosulfonamidophenyl)carbonyl)-1-piperidinyl)ethanone hydrochloride; N-[4-[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide hydrochloride; Methanesulfonamide, N-(4-((1-(2-(4-fluorophenyl)-2-oxoethyl)-4-piperidinyl)carbonyl)phenyl)-, monohydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Thrombosis	DB61-GB90	Terminated	[1]

Cross-matching ID

PubChem CID: 132001
CAS Number: CAS 136861-96-6
TTD Drug ID: DM6X4IT

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting 5-HT 2 receptor (5HT2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mianserin	DMVKA4O	Depression	6A70-6A7Z	Approved	[3]
Cyclobenzaprine	DM1YBRM	Depression	6A70-6A7Z	Approved	[4]
Perospirone	DMVHJLX	Psychotic disorder	6A20-6A25	Approved	[5]
Ketanserin	DMVLMW6	Hypertension	BA00-BA04	Approved	[6]
Bis(olanzapine) pamoate monohydrate	DME76AP	Psychotic disorder	6A20-6A25	Phase 3	[7]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[8]
Nexopamil	DML5S71	Hypertension	BA00-BA04	Phase 2	[9]
TGWOOAA	DMI57ZA	Generalized anxiety disorder	6B00	Phase 2	[10]
TGOF02N	DMQ6ANE	Schizophrenia	6A20	Phase 2	[11]
AMAP-102	DM7CD8Z	Arthritis	FA20	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2 receptor (5HT2R)	TTYSN63	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002814)
2	Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs. J Cardiovasc Pharmacol. 1994 Nov;24(5):761-72.
3	5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6.
4	Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92.
5	Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Pharmacopsychiatry. 1993 Mar;26(2):53-8.
6	Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
10	Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
11	Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
12	Clinical pipeline report, company report or official report of Anamar.